YZ-0235

YZ-0235 is a preclinical-stage small molecule inhibitor targeting the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. Developed by Guangdong Yinzhu Pharmaceutical Technology, it is being investigated for the treatment of ALK-positive non-small cell lung cancer (NSCLC), specifically in combination with the ALK inhibitor alectinib. The rationale for this combination likely involves overcoming resistance mechanisms or enhancing the apoptotic effect of ALK inhibition through the modulation of NF-κB signaling, which is often implicated in cell survival and drug resistance in various cancers.